Compare Gilead Sciences, Inc. (GILD) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Reddit Inc — how do they compare? Gilead Sciences, Inc. trades at $133.18 (market cap $163.51B), while Reddit Inc trades at $190.85 (market cap $38.12B). The key difference: Gilead Sciences, Inc. is far larger — about 4.3× Reddit Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Reddit Inc pays none. Which is the better fit depends on your goals.
| GILD | RDDT | |
|---|---|---|
Market Cap | $163.51B | $38.12B |
Sector | Health | Media |
52-Week High | $155.80 | $270.71 |
52-Week Low | $108.22 | $121.84 |
Enterprise Value | $178.05B | $35.37B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Reddit (RDDT) trades at $193.79, down 4.65% in the last session, with a bullish technical signal from moving averages. The company shows strong fundamentals with 91.37% gross margins and 28.6% net income margin, though valuation ratios remain elevated (P/E 56.58). Recent earnings beat expectations in two of the last three quarters, with Q2 2026 results due July 30, 2026.
Outlook remains positive with analyst consensus at Buy (63%) and $236.89 price target, representing 22% upside. Key risks include high valuation multiples and competitive digital advertising pressures. Revenue growth trajectory and AI safety initiatives position RDDT for sustained expansion if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
